View Financial HealthMolecular Data 배당 및 자사주 매입배당 기준 점검 0/6Molecular Data 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Oct 27Nasdaq Stock Market to Delist the American Depositary Shares of Molecular Data IncOn October 26, 2022, Nasdaq Stock Market announced that it will delist the American Depositary Shares of Molecular Data Inc. Molecular Data’s securities were suspended on September 7, 2022, and have not traded on Nasdaq since that time. Nasdaq will file a Form 25 with the Securities and Exchange Commission to complete the delisting. The delisting become effective ten days after the Form 25 is filed.Board Change • Aug 02High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. Independent Director Dawei Ma is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.공시 • Jun 25Molecular Data Receives NASDAQ NotificationMolecular Data Inc. announced that it had received a letter from The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that to date, it has not regained compliance with the Rule 5250(c)(1). Since the Company is already before a Hearings Panel for its failure to comply with the $1.00 minimum bid price requirement set forth in Listing Rule 5550(a)(2),pursuant to Listing Rule 5810(d)(2), rather than submit a compliance plan for Staff's review, the Company is to address the matter before the Hearings Panel.공시 • May 29Molecular Data Inc. Receives NASDAQ Notification Regarding Minimum Bid RequirementsMolecular Data Inc. announced that on May 25, 2021, it had received a letter from The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that its minimum closing bid price per share for its ordinary shares had fallen below $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). On November 29, 2021, the Company was provided with an additional 180 calendar day compliance period, or until May 23, 2022, to demonstrate compliance. On May 24, 2022, the Company received notice from Nasdaq that it has not regained compliance with Listing Rule 5550(a)(2) and that its American Depository Shares ("ADS") would be delisted from the Capital Markets and a Form 25- NSE filed with the Securities and Exchange Commission (the "SEC") to remove the Company's securities from listing and registration on The Nasdaq Stock Market unless the Company requests a hearing for an appeal. On May 26, 2022, the Company submitted a hearing request to a Hearings Panel (the "Panel") for an appeal pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. The hearing request will stay the suspension and delisting action pending the issuance of a written Panel decision.공시 • May 21Molecular Data Announces Receipt of Nasdaq Non-Compliance LetterOn May 20, 2022, Molecular Data Inc. announced that on May 17, 2022, it received a Delinquency Compliance Plan Alert Letter (the "Letter") from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1), because it has not timely filed its annual report on Form 20-F for the period ended December 31, 2021. In the Letter, Nasdaq stated that the Company has 60 calendar days to submit a plan to regain compliance. If Nasdaq accepts the Company's plan, Nasdaq can grant the Company an exception of up to 180 calendar days from the Company's Form 20-F's filing due date, or until November 14, 2022, to regain compliance.공시 • May 03Molecular Data Inc. announced delayed 20-F filingOn 05/02/2022, Molecular Data Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC.Board Change • Apr 27High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. Independent Director Dawei Ma is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.공시 • Dec 08Molecular Data Inc. Adopts Blockchain to Enhance its PlatformMolecular Data Inc. has upgraded its platform using Blockchain for its current chemical business. With properties of Blockchain including traceability and transparency, such an adoption can be applied in numerous processes from the front to back end in the current business to improve credibility. Also, the transactions efficiency and safety will be enhanced.Reported Earnings • Oct 07First half 2021 earnings released: CN¥0.22 loss per shareThe company reported a decent first half result with reduced losses and improved control over expenses, although revenues were weaker. First half 2021 results: Revenue: CN¥1.46b (down 67% from 1H 2020). Net loss: CN¥32.8m (loss narrowed 69% from 1H 2020).공시 • Sep 24Molecular Data Inc. has completed a Composite Units Offering in the amount of $14.998392 million.Molecular Data Inc. has completed a Composite Units Offering in the amount of $14.998392 million. Security Name: Common Units Security Type: Equity/Derivative Unit Securities Offered: 23,390,000 Price\Range: $0.38 Discount Per Security: $0.0304 Security Name: Pre-Funded Units Security Type: Equity/Derivative Unit Securities Offered: 16,083,684 Price\Range: $0.3799 Discount Per Security: $0.030392 Transaction Features: Registered Direct Offering공시 • Jul 15Molecular Data Inc. announced that it expects to receive $1.9 million in funding from Yorkville Advisors Global LPMolecular Data Inc. announced that it has entered into a securities purchase agreement with returning investor, YA II PN, Ltd., a fund managed by Yorkville Advisors Global LP for a private placement of convertible debentures for gross proceeds of $1,900,000 on July 14, 2021. The convertible debentures bear interest of 5% per year. The securities are issued at a discount of 5%. The investor shall be entitled to convert any portion of the outstanding and unpaid conversion amount into fully paid and nonassessable ordinary Shares. The debenture will mature on July 14, 2022 unless earlier converted or redeemed. Upon conversion, the company will issue American depositary shares to the investor. The initial conversion price shall be the lower of $1.30 per share, or 88% of a reference price benchmarked against trading price of the company's shares. Each American depositary share represents three class A ordinary shares of the company.공시 • May 04Molecular Data Inc. announced delayed 20-F filingOn 05/03/2021, Molecular Data Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC.공시 • Apr 10Molecular Data Inc. announced that it has received $7.5 million in fundingMolecular Data Inc. (NasdaqCM:MKD) announced that it has raised up to $7.5 million in a round of funding from accredited investor on April 9, 2021.공시 • Mar 11Molecular Data Inc. Enters Supply Framework Agreement with Anhui Gujing Distillery Co., LtdMolecular Data Inc. announced that it has entered into a supply framework agreement with Anhui Gujing Distillery Co. Ltd. ("Gujing"), one of the most important core enterprises in China's liquor market, as part of its efforts to expand presence in the food and beverage industry. Under the agreement, Molecular Data will become a key supplier for Gujing and its affiliated companies, including Anhui Runan Xinke Testing Technology Co. Ltd.("Runan Xinke") and Anhui Ruisi Weier Technology Co. Ltd. ("Ruisi Weier"), in the fields of chemical reagents, biological reagents, laboratory consumables, as well as related instruments and equipment. Molecular Data will source nearly 2 million stock-keeping units (SKUs) that Gujing requires from its 21 well-known domestic and foreign laboratory brands and suppliers. Molecular Data'sMKD Lab Supplies Mall is a data-driven one-stop laboratory supplies e-commerce service platform, which covers all categories of chemical reagents, biological reagents, laboratory consumables, and equipment. The mall serves scientific research institutions, hospitals, university laboratories, third-party testing units and production plants, providing procurement services that include all categories of reagents and intermediates. With a history of more than 1,800 years, Gujing Gongjiu is one of the eight most prestigious liquor brands in China, and has won the gold medal in the national spirits appraisal four times consecutively. Gujing's research capabilities in liquor are also industry leading. In accordance with the national standards of top laboratories, Gujing has established research and development centers, national post-doctoral research workstations, academic workstations, national food enterprise quality and safety testing technology demonstration centers and other scientific research platforms. Both affiliates of Gujing, Runan Xinke is a state-owned third-party testing institution that provides one-stop testing services from inspection to testing and technical services with various national certification; while Ruisi Weier has been striving for technology development related to biological fermentation engineering. The collaboration with Gujing is another milestone for Molecular Datato propel digitalization of the traditional industries and empower intelligent manufacturing in China. Molecular Data will continue to optimize supply chain services and upgrade the digital products, helping enterprises both from China and abroad to reduce costs and increase efficiency to spur the development of the industry.Is New 90 Day High Low • Feb 13New 90-day high: US$1.87The company is up 68% from its price of US$1.11 on 13 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Online Retail industry, which is up 10.0% over the same period.분석 기사 • Jan 16What Percentage Of Molecular Data Inc. (NASDAQ:MKD) Shares Do Insiders Own?The big shareholder groups in Molecular Data Inc. ( NASDAQ:MKD ) have power over the company. Insiders often own a...Is New 90 Day High Low • Jan 16New 90-day low: US$0.80The company is down 28% from its price of US$1.12 on 16 October 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is flat over the same period.공시 • Dec 30Molecular Data Inc. Announces Cessation of Dongliang Chang as Member of the Audit Committee of the Board of DirectorsMolecular Data Inc. announced that Dr. Dongliang Chang ceases to serve as a member of the audit committee of the board of directors of the Company, effective immediately to ensure audit committee independence. Dr. Chang will continue to serve as the Chairman of Board of Directors.Is New 90 Day High Low • Dec 28New 90-day low: US$0.85The company is down 25% from its price of US$1.13 on 29 September 2020. The American market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 3.0% over the same period.공시 • Dec 03Molecular Data Inc. Announces Management ChangesMolecular Data Inc. announced that the Company has appointed Mr. Steven Foo as the new chief financial officer, effective December 1, 2020. Mr. Zhaohong Li has tendered his resignation as chief financial officer, for personal reasons. Mr. Foo brings over 24 years of investment, financing experience as well as financial management and restructuring work experience in Asia. Previously, Mr. Foo served as a member of the board of directors and chief financial officer of SOS Health Rescue Services. Prior to that, Mr. Foo served as a member of the board of directors and chief financial officer of Hebron Technology. Mr. Foo is a Fellow Chartered Accountant and Certified Public Accountant (CPA). In addition to his experience in securities laws and regulations compliance, Mr. Foo has extensive leadership experience in strategy, financial management and capital markets.Is New 90 Day High Low • Dec 02New 90-day low: US$1.04The company is down 11% from its price of US$1.17 on 03 September 2020. The American market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is down 4.0% over the same period.Is New 90 Day High Low • Oct 16New 90-day low: US$1.09The company is down 62% from its price of US$2.87 on 17 July 2020. The American market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 15% over the same period.공시 • Sep 29Li Li to Step Down as Vice President of Molecular Data Inc., Effective September 29, 2020Molecular Data Inc. announced that Mr. Li Li, co-founder and vice president of the Company, will step down from his current position for personal reasons, effective September 29, 2020, and will serve as the vice president of the strategy advisory committee of the Company.Is New 90 Day High Low • Sep 24New 90-day low: US$1.11The company is down 42% from its price of US$1.91 on 26 June 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 15% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 MKDT.Y 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: MKDT.Y 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Molecular Data 배당 수익률 vs 시장MKDT.Y의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (MKDT.Y)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Trade Distributors)1.4%분석가 예측 (MKDT.Y) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 MKDT.Y 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 MKDT.Y 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 MKDT.Y 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: MKDT.Y 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/20 01:07종가2026/05/14 00:00수익2021/06/30연간 수익2020/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Molecular Data Inc.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullArgus Research Company
공시 • Oct 27Nasdaq Stock Market to Delist the American Depositary Shares of Molecular Data IncOn October 26, 2022, Nasdaq Stock Market announced that it will delist the American Depositary Shares of Molecular Data Inc. Molecular Data’s securities were suspended on September 7, 2022, and have not traded on Nasdaq since that time. Nasdaq will file a Form 25 with the Securities and Exchange Commission to complete the delisting. The delisting become effective ten days after the Form 25 is filed.
Board Change • Aug 02High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. Independent Director Dawei Ma is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
공시 • Jun 25Molecular Data Receives NASDAQ NotificationMolecular Data Inc. announced that it had received a letter from The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that to date, it has not regained compliance with the Rule 5250(c)(1). Since the Company is already before a Hearings Panel for its failure to comply with the $1.00 minimum bid price requirement set forth in Listing Rule 5550(a)(2),pursuant to Listing Rule 5810(d)(2), rather than submit a compliance plan for Staff's review, the Company is to address the matter before the Hearings Panel.
공시 • May 29Molecular Data Inc. Receives NASDAQ Notification Regarding Minimum Bid RequirementsMolecular Data Inc. announced that on May 25, 2021, it had received a letter from The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that its minimum closing bid price per share for its ordinary shares had fallen below $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). On November 29, 2021, the Company was provided with an additional 180 calendar day compliance period, or until May 23, 2022, to demonstrate compliance. On May 24, 2022, the Company received notice from Nasdaq that it has not regained compliance with Listing Rule 5550(a)(2) and that its American Depository Shares ("ADS") would be delisted from the Capital Markets and a Form 25- NSE filed with the Securities and Exchange Commission (the "SEC") to remove the Company's securities from listing and registration on The Nasdaq Stock Market unless the Company requests a hearing for an appeal. On May 26, 2022, the Company submitted a hearing request to a Hearings Panel (the "Panel") for an appeal pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. The hearing request will stay the suspension and delisting action pending the issuance of a written Panel decision.
공시 • May 21Molecular Data Announces Receipt of Nasdaq Non-Compliance LetterOn May 20, 2022, Molecular Data Inc. announced that on May 17, 2022, it received a Delinquency Compliance Plan Alert Letter (the "Letter") from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1), because it has not timely filed its annual report on Form 20-F for the period ended December 31, 2021. In the Letter, Nasdaq stated that the Company has 60 calendar days to submit a plan to regain compliance. If Nasdaq accepts the Company's plan, Nasdaq can grant the Company an exception of up to 180 calendar days from the Company's Form 20-F's filing due date, or until November 14, 2022, to regain compliance.
공시 • May 03Molecular Data Inc. announced delayed 20-F filingOn 05/02/2022, Molecular Data Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC.
Board Change • Apr 27High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. 1 experienced director. No highly experienced directors. Independent Director Dawei Ma is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
공시 • Dec 08Molecular Data Inc. Adopts Blockchain to Enhance its PlatformMolecular Data Inc. has upgraded its platform using Blockchain for its current chemical business. With properties of Blockchain including traceability and transparency, such an adoption can be applied in numerous processes from the front to back end in the current business to improve credibility. Also, the transactions efficiency and safety will be enhanced.
Reported Earnings • Oct 07First half 2021 earnings released: CN¥0.22 loss per shareThe company reported a decent first half result with reduced losses and improved control over expenses, although revenues were weaker. First half 2021 results: Revenue: CN¥1.46b (down 67% from 1H 2020). Net loss: CN¥32.8m (loss narrowed 69% from 1H 2020).
공시 • Sep 24Molecular Data Inc. has completed a Composite Units Offering in the amount of $14.998392 million.Molecular Data Inc. has completed a Composite Units Offering in the amount of $14.998392 million. Security Name: Common Units Security Type: Equity/Derivative Unit Securities Offered: 23,390,000 Price\Range: $0.38 Discount Per Security: $0.0304 Security Name: Pre-Funded Units Security Type: Equity/Derivative Unit Securities Offered: 16,083,684 Price\Range: $0.3799 Discount Per Security: $0.030392 Transaction Features: Registered Direct Offering
공시 • Jul 15Molecular Data Inc. announced that it expects to receive $1.9 million in funding from Yorkville Advisors Global LPMolecular Data Inc. announced that it has entered into a securities purchase agreement with returning investor, YA II PN, Ltd., a fund managed by Yorkville Advisors Global LP for a private placement of convertible debentures for gross proceeds of $1,900,000 on July 14, 2021. The convertible debentures bear interest of 5% per year. The securities are issued at a discount of 5%. The investor shall be entitled to convert any portion of the outstanding and unpaid conversion amount into fully paid and nonassessable ordinary Shares. The debenture will mature on July 14, 2022 unless earlier converted or redeemed. Upon conversion, the company will issue American depositary shares to the investor. The initial conversion price shall be the lower of $1.30 per share, or 88% of a reference price benchmarked against trading price of the company's shares. Each American depositary share represents three class A ordinary shares of the company.
공시 • May 04Molecular Data Inc. announced delayed 20-F filingOn 05/03/2021, Molecular Data Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC.
공시 • Apr 10Molecular Data Inc. announced that it has received $7.5 million in fundingMolecular Data Inc. (NasdaqCM:MKD) announced that it has raised up to $7.5 million in a round of funding from accredited investor on April 9, 2021.
공시 • Mar 11Molecular Data Inc. Enters Supply Framework Agreement with Anhui Gujing Distillery Co., LtdMolecular Data Inc. announced that it has entered into a supply framework agreement with Anhui Gujing Distillery Co. Ltd. ("Gujing"), one of the most important core enterprises in China's liquor market, as part of its efforts to expand presence in the food and beverage industry. Under the agreement, Molecular Data will become a key supplier for Gujing and its affiliated companies, including Anhui Runan Xinke Testing Technology Co. Ltd.("Runan Xinke") and Anhui Ruisi Weier Technology Co. Ltd. ("Ruisi Weier"), in the fields of chemical reagents, biological reagents, laboratory consumables, as well as related instruments and equipment. Molecular Data will source nearly 2 million stock-keeping units (SKUs) that Gujing requires from its 21 well-known domestic and foreign laboratory brands and suppliers. Molecular Data'sMKD Lab Supplies Mall is a data-driven one-stop laboratory supplies e-commerce service platform, which covers all categories of chemical reagents, biological reagents, laboratory consumables, and equipment. The mall serves scientific research institutions, hospitals, university laboratories, third-party testing units and production plants, providing procurement services that include all categories of reagents and intermediates. With a history of more than 1,800 years, Gujing Gongjiu is one of the eight most prestigious liquor brands in China, and has won the gold medal in the national spirits appraisal four times consecutively. Gujing's research capabilities in liquor are also industry leading. In accordance with the national standards of top laboratories, Gujing has established research and development centers, national post-doctoral research workstations, academic workstations, national food enterprise quality and safety testing technology demonstration centers and other scientific research platforms. Both affiliates of Gujing, Runan Xinke is a state-owned third-party testing institution that provides one-stop testing services from inspection to testing and technical services with various national certification; while Ruisi Weier has been striving for technology development related to biological fermentation engineering. The collaboration with Gujing is another milestone for Molecular Datato propel digitalization of the traditional industries and empower intelligent manufacturing in China. Molecular Data will continue to optimize supply chain services and upgrade the digital products, helping enterprises both from China and abroad to reduce costs and increase efficiency to spur the development of the industry.
Is New 90 Day High Low • Feb 13New 90-day high: US$1.87The company is up 68% from its price of US$1.11 on 13 November 2020. The American market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Online Retail industry, which is up 10.0% over the same period.
분석 기사 • Jan 16What Percentage Of Molecular Data Inc. (NASDAQ:MKD) Shares Do Insiders Own?The big shareholder groups in Molecular Data Inc. ( NASDAQ:MKD ) have power over the company. Insiders often own a...
Is New 90 Day High Low • Jan 16New 90-day low: US$0.80The company is down 28% from its price of US$1.12 on 16 October 2020. The American market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is flat over the same period.
공시 • Dec 30Molecular Data Inc. Announces Cessation of Dongliang Chang as Member of the Audit Committee of the Board of DirectorsMolecular Data Inc. announced that Dr. Dongliang Chang ceases to serve as a member of the audit committee of the board of directors of the Company, effective immediately to ensure audit committee independence. Dr. Chang will continue to serve as the Chairman of Board of Directors.
Is New 90 Day High Low • Dec 28New 90-day low: US$0.85The company is down 25% from its price of US$1.13 on 29 September 2020. The American market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 3.0% over the same period.
공시 • Dec 03Molecular Data Inc. Announces Management ChangesMolecular Data Inc. announced that the Company has appointed Mr. Steven Foo as the new chief financial officer, effective December 1, 2020. Mr. Zhaohong Li has tendered his resignation as chief financial officer, for personal reasons. Mr. Foo brings over 24 years of investment, financing experience as well as financial management and restructuring work experience in Asia. Previously, Mr. Foo served as a member of the board of directors and chief financial officer of SOS Health Rescue Services. Prior to that, Mr. Foo served as a member of the board of directors and chief financial officer of Hebron Technology. Mr. Foo is a Fellow Chartered Accountant and Certified Public Accountant (CPA). In addition to his experience in securities laws and regulations compliance, Mr. Foo has extensive leadership experience in strategy, financial management and capital markets.
Is New 90 Day High Low • Dec 02New 90-day low: US$1.04The company is down 11% from its price of US$1.17 on 03 September 2020. The American market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is down 4.0% over the same period.
Is New 90 Day High Low • Oct 16New 90-day low: US$1.09The company is down 62% from its price of US$2.87 on 17 July 2020. The American market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 15% over the same period.
공시 • Sep 29Li Li to Step Down as Vice President of Molecular Data Inc., Effective September 29, 2020Molecular Data Inc. announced that Mr. Li Li, co-founder and vice president of the Company, will step down from his current position for personal reasons, effective September 29, 2020, and will serve as the vice president of the strategy advisory committee of the Company.
Is New 90 Day High Low • Sep 24New 90-day low: US$1.11The company is down 42% from its price of US$1.91 on 26 June 2020. The American market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Online Retail industry, which is up 15% over the same period.